PLEASANTON, Calif.–(BUSINESS WIRE)–RadiusXR, the trailblazer in Digital Well being, pronounces the publication of its groundbreaking NOVA Medical Trial in Translational Imaginative and prescient Science and Expertise (TVST), a prestigious journal by the Affiliation for Analysis in Imaginative and prescient and Ophthalmology (ARVO). This milestone publication confirms RadiusXR’s unwavering dedication to advancing ocular well being and heralds a brand new period in visible area testing.
“Our proprietary expertise, mixed with spatial computing, delivers unparalleled accuracy and precision, revolutionizing the prognosis and administration of ocular circumstances.”
Publish this
The NOVA Medical Trial has revealed outstanding findings, together with statistical non-inferiority to present medical requirements for sensitivities at particular person take a look at places, glaucoma staging utilizing Medicare definitions, and an exceptionally excessive correlation of 0.94 in imply deviation.1 These outcomes underscore the unparalleled accuracy and reliability of RadiusXR’s method to visible area testing for head-mounted digital actuality perimetry.
Furthermore, not like different digital actuality perimeters (VRPs), RadiusXR measures imaginative and prescient throughout the photopic vary, aligning with current visible area platforms’ requirements. This alignment permits constant medical coaching and facilitates comparability to sufferers’ prior examinations, as normative databases and imply deviation/sample normal deviation (MD/PSD) plots are based mostly on the photopic vary. RadiusXR’s steadfast adherence to business requirements ensures seamless integration into medical apply and enhances affected person care.
“The publication of the NOVA Medical Trial in TVST reaffirms RadiusXR’s place because the chief in visible area testing innovation,” remarked Ammad Khan, RadiusXR’s Chief Government Officer. “Our proprietary expertise, mixed with spatial computing, delivers unparalleled accuracy and precision, revolutionizing the prognosis and administration of ocular circumstances.”
Dr. Thomas Samuelson, a distinguished ophthalmologist at Minnesota Eye Consultants in Minneapolis, expressed, “The findings from the NOVA Medical Trial are really groundbreaking. RadiusXR’s progressive method to visible area testing represents a major development within the area of ophthalmology. This expertise can doubtlessly revolutionize how we diagnose and handle ocular circumstances, in the end enhancing affected person outcomes and high quality of life.”
In July 2023, RadiusXR introduced it entered right into a collaboration and advertising settlement with Glaukos Company, a number one ophthalmic pharmaceutical and medical expertise firm, whereby Glaukos turned the unique gross sales agent to market, promote, and solicit orders for RadiusXR in the US. Radius continues to steer growth and commercialization efforts for RadiusXR.
The whole particulars of the NOVA Medical Trial can be found right here > https://tvst.arvojournals.org/article.aspx?articleid=2793455
For extra details about RadiusXR and its superior applied sciences, please go to radiusxr.com
